Premium
Prognostic factors and expression of p53 and mdm‐2 in uterine sarcomas
Author(s) -
Kim S.H.,
Kim J.W.,
Kim Y.T.,
Kim J.H.,
Yoon B.S.,
Ryu H.S.
Publication year - 2006
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2006.03.031
Subject(s) - uterine sarcoma , medicine , mitotic index , immunohistochemistry , sarcoma , stage (stratigraphy) , overall survival , oncology , pathology , cancer research , mitosis , biology , paleontology , microbiology and biotechnology
Abstract Objectives: To evaluate the clinicopathologic prognostic factors of uterine sarcoma, and determine whether overexpression of p53 and mdm‐2 proteins correlate with overall survival and prognostic factors. Methods: Thirty specimens from 43 patients with uterine sarcoma were available for slide review and evaluated by immunohistochemistry at Yonsei and Ajou University Medical Centers for the expression of p53 and mdm‐2. Results: Overall survival was found to correlate to histologic type of uterine sarcoma, surgical stage, tumor grade, and mitotic index. Whereas 63% of the sarcomas expressed p53, with a significant correlation to overall survival, 60% expressed mdm‐2, with a significant correlation to the mitotic index but not to overall survival. Conclusion: Histologic type, surgical stage, tumor grade, mitotic index, and p53 expression were prognostic factors of the overall survival of patients with uterine sarcoma.